THDB: Insulin Glargine Injection has obtained overseas listing approval

Zhitong
2025.10.10 09:07
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, THDB announced that the company recently received the marketing authorization for its product Insulin Glargine Injection issued by the Ministry of Health of the Republic of the Union of Myanmar. Insulin Glargine is a long-acting insulin analog product that is injected once daily, with an effect duration of up to 24 hours after injection, providing a peakless blood concentration and steadily lowering the patient's blood sugar levels

According to the Zhitong Finance APP, THDB (600867.SH) announced that the company recently received the marketing authorization for its product, Insulin Glargine Injection, issued by the Ministry of Health of the Republic of the Union of Myanmar.

Insulin Glargine is a long-acting insulin analog product that is injected once daily, with an effect duration of up to 24 hours after injection, providing a steady reduction in blood sugar levels without peak concentrations

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer